NCT05641272 (MM09-SLIM) is a Phase 2, PHASE3 clinical trial of 3,000 MM09 in Allergic Rhinitis, sponsored by Inmunotek S.L..

Who is sponsoring NCT05641272?

NCT05641272 is sponsored by Inmunotek S.L..

What drugs are being tested in NCT05641272?

Interventions in NCT05641272: 3,000 MM09, 9,000 MM09, Placebo sublingual.

What condition does NCT05641272 study?

NCT05641272 studies Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite.

Is NCT05641272 still recruiting?

NCT05641272 is currently not yet recruiting. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT05641272: MM09-SLIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Not yet recruiting Phase 2, PHASE3 Last updated 23 October 2023

What this trial tests

Phase 2, PHASE3 trial testing 3,000 MM09 in Allergic Rhinitis in 90 participants. Not yet recruiting.

Timeline

1 November 2023

Primary endpoint
1 June 2026

1 December 2026

Quick facts

Lead sponsor	Inmunotek S.L.
Phase	Phase 2, PHASE3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	90
Start date	1 November 2023
Primary completion	1 June 2026
Estimated completion	1 December 2026
Sites	1 location across Argentina

Drugs / interventions tested

3,000 MM09 — full drug profile →
9,000 MM09 — full drug profile →
Placebo sublingual

Conditions studied

Allergic Rhinitis — all drugs for Allergic Rhinitis →
Allergic Asthma — all drugs for Allergic Asthma →
Allergic Rhinoconjunctivitis — all drugs for Allergic Rhinoconjunctivitis →
Allergy to House Dust Mite — all drugs for Allergy to House Dust Mite →

Sponsor

Inmunotek S.L. — full company profile →

Who can join

Adults 12 to 60, any sex, with Allergic Rhinitis or Allergic Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic rhinitis/rhinoconjunctivitis with or without asthma. The main objective of the clinical trial is to evaluate the clinical efficacy of the investigational medicinal product, administered sublingually, compared to placebo for the treatment of moderate-severe rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and controlled using the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (R-CSMS).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New progress in pediatric allergic rhinitis.
Cheng M, Dai Q, Liu Z, Wang Y, et al · · 2024 · cited 10× · PMID 39351215 · DOI 10.3389/fimmu.2024.1452410

Verify or expand the search:

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting

Other Inmunotek S.L. trials

Trials by the same sponsor.

NCT07427576 — Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte · completed
NCT06790368 — Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions. · recruiting
NCT06957496 — Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization · NA · completed
NCT06782217 — Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy · recruiting
NCT05533385 — Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05641272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inmunotek S.L.
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05641272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing